Laddar populära aktier...
Vitrolife’s Q1 shows that the headwind for Genetics will likely last until mid-2024.
Redeye updates on Invisio ahead of its Q1-results (due 7 May) where we expect a strong order intake ...
Redeye updates its estimates and valuation following ADDvise releasing its Q1 2024 report, which fea...
Elanders presented a mixed Q1 report, with a high single-digit organic sales decline, as Fashion saw...
Q1 weaker than expected... ...but outlook remains bright Low valuation and leverage on market, lower...
Plejds nettoomsättning för det fjärde kvartalet 2023 uppgick till 159,0 MSEK (121,3), en ökning med ...
Flat organic sales growth, due to Genetics EBITDA revised down 1.
Redeye revisits its market share assumptions for BONESUPPORT’s extremities business.
Redeye comments on Safeture's Q1 2024 report, which was stable despite higher churn.
Redeye updates its outlook on Hansa Biopharma, anticipating improved launch support during 2024 and ...
Redeye comments on Freemelt’s first industrial printer (eMelt) order in the US and provides a previe...
Q1e: Clean EBIT of PLN 87m Paper is improving – better demand and 10% supply cuts Fair value range o...
'24e-'26e ARR cut by 2-3% on continued macro weakness B2C business momentum likely to return in H2'2...
Tangiamo Touch Technology meddelade den 16 april 2024 att bolaget har erhållit en order värd cirka 1...
Inför Q1: marknadsdata indikerar underliggande tillväxt i Sverige Vi förväntar oss en omsättningstil...